Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Axel Merseburger, from the Schleswig-Holstein University Hospital, Lübeck, Germany, discusses the currently available androgen deprivation therapies (ADT) at the European Association of Urology (EAU) conference 2017 in London, UK. He argues that an important factor is which ADT is used, as they have different mechanisms of action and response times.
We use necessary cookies to make this site work. Analytics, preference, and marketing cookies are used only if you choose to allow them. You can change your choice at any time. For more information view our Cookie Policy.